中药创新是中药现代化的核心驱动力。如何借助现代生命科学的理论技术实现中药研发的创新，成为亟待解决的问题。目前，国际上正在步入以单一靶点发展为多靶点药物组合，以活性成分筛选转变为药动学优化设计为导向的新一轮研发热潮中。面对研发模式的转变，我国中药的研发多数仍停留在以质量控制、药效活性筛选等初始环节。结合系统生物学和黄芩汤提取物（PHY906）中有关中药研发的内容，引入“药动学先行”这一概念，旨在将药动学作为快速筛选定位中药中具有潜在研究价值活性成分的工具。并进一步对中药研发模式为何需要“药动学先行”以及如何展开这一创新模式研究进行探讨。

The innovation of Chinese materia medica (CMM) is the central driver of CMM modernization. The application of modern theories and techniques in life sciences to innovating CMM research remains to be an urgent issue to be solved. Currently, the international R&D for drug is stepping into a new trend, in which these transformations are going through a signal target to multiple drug combination and active constituents selection by pharmacodynamics to optimize the design with pharmacokinetics. In the face of changes, the pace of CMM R&D is slow. Based on the R&D content of system biology and Huangqin Decoction extract (PHY906), the “preceded pharmacokinetics” concept is introduced. Taking pharmacokinetics as the tool to rapidly screen the potential constituents with the aims at CMM R&D. Furthermore, why the “preceded pharmacokinetics” is needed and how to start the innovation model are preliminarily discussed in this paper.